Bedrocan International is returning to the Canadian medicinal cannabis market. The company purchased a facility in Scarborough, the former home of Bedrocan in Canada, and was recently granted a cultivation license by Health Canada. These steps fulfill Bedrocan's long-held promise of returning to Canada to grow standardized medicinal cannabis for Canadian patients. The company intends to start production in early 2025.
The intention is for Bedrocan to bring several standardized cannabis products to the Canadian market of which the Bedrocan product is the most well-known. The cannabis products will be distributed through a third party via the medical sales channel to registered patients.
Bedrocan was previously active in Canada but ceased its activities after a partnership with Canopy Growth was terminated. Bedrocan has always expressed its intention to return to Canada one day.
Bedrocan's CEO Jaap Erkelens said: "We are thrilled to be coming back to Canada. "We look forward to serving patients in Canada and positively impacting the Canadian healthcare landscape."
For more information:
Bedrocan
www.bedrocan.com